MELVILLE, N.Y.–(HSMN NewsFeed)–OSI Pharmaceuticals, Inc. (NASDAQ: OSIP ) today announced further results from the Phase III SATURN study showing that Tarceva(R) (erlotinib) extended the survival of patients with advanced non-small cell lung cancer (NSCLC…
Biopharmaceuticals, Oncology
OSI Pharmaceuticals, Genentech, Tarceva, erlotinib, lung cancer, NSCLC
Nail Your Sales Interview with the 30/60/90 Day Sales Plan
If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.Now you can nail your interview with the 30 60 90 Day Sales Plan template with Audio Coaching. This simple tool will help you knock the socks off your interviewer and bury your competition.
To get the details: Click Here
